Epigenetic Modification of Castor Zinc Finger 1 (CASZ1) is Associated with Tumor Microenvironments and Prognosis of Clear Cell Renal Cell Carcinoma

Overview

Journal Int J Surg

Specialty General Surgery

Date 2024 Sep 5

PMID 39235847

Authors

Fei Li

Jiayu Liang

Xin Wei

Affiliations

Soon will be listed here.

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) represents the predominant and remarkably diverse form of renal cell carcinoma. The involvement of the Castor zinc finger 1 (CASZ1) gene in adverse prognostic outcomes has been observed across different cancer types. Nevertheless, the specific altered activities and associated multi-omics characteristics of CASZ1 in ccRCC remain unelucidated.

Method: In order to explore the expression of CASZ1, evaluate its prognostic significance, and aid in the therapeutic decision-making process for patients with ccRCC, The Cancer Genome Atlas (TCGA), Gene expression omnibus (GEO), and The Human Protein Atlas (HPA) databases were utilized to gather data on clinicopathological data, prognostic information, genomic, methylomic and immunomic data. Additionally, the Genomics of Drug Sensitivity in Cancer (GDSC) database provided information on drug sensitivity.

Results: CASZ1 expression was found to be significantly reduced in ccRCC and was associated with unfavorable pathological characteristics and a bleak prognosis. Diminished CASZ1 mRNA levels were notably correlated with heightened cytosine-phosphate-guanine (CpG) methylation, indicating a poorer prognosis for patients with increased methylation. Examination of RNA-seq data from TCGA indicated that the CASZ1-high expression subgroup displayed heightened immune cell infiltration and increased expression of immune checkpoint markers, potentially suggesting a more favorable response to immunotherapy. Furthermore, data from the GDSC database indicated that the CASZ1-low expression subgroup might exhibit greater sensitivity to anti-angiogenetic treatments, such as Sunitinib and Axitinib.

Conclusions: These results indicate that CASZ1 may function as a biomarker for distinguishing various tumor microenvironment phenotypes, predicting prognosis, and assisting in treatment decisions for individuals with ccRCC.

Citing Articles

The role and mechanism of NAT10-mediated ac4C modification in tumor development and progression.

Gu Z, Zou L, Pan X, Yu Y, Liu Y, Zhang Z MedComm (2020). 2024; 5(12):e70026.

PMID: 39640362 PMC: 11617596. DOI: 10.1002/mco2.70026.

References

Kim B, Jung M, Moon K . The Prognostic Significance of Protein Expression of CASZ1 in Clear Cell Renal Cell Carcinoma. Dis Markers. 2019; 2019:1342161. PMC: 6701416. DOI: 10.1155/2019/1342161. View

Li Y, Ge D, Lu C . The SMART App: an interactive web application for comprehensive DNA methylation analysis and visualization. Epigenetics Chromatin. 2019; 12(1):71. PMC: 6894252. DOI: 10.1186/s13072-019-0316-3. View

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

Barata P, Rini B . Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 2017; 67(6):507-524. DOI: 10.3322/caac.21411. View

Jonasch E, Gao J, Rathmell W . Renal cell carcinoma. BMJ. 2014; 349:g4797. PMC: 4707715. DOI: 10.1136/bmj.g4797. View

Riaz I, He H, Ryu A, Siddiqi R, Naqvi S, Yao Y . A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. Eur Urol. 2021; 80(6):712-723. DOI: 10.1016/j.eururo.2021.03.016. View

Barrett T, Wilhite S, Ledoux P, Evangelista C, Kim I, Tomashevsky M . NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2012; 41(Database issue):D991-5. PMC: 3531084. DOI: 10.1093/nar/gks1193. View

Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L . CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell Death Differ. 2011; 18(7):1174-83. PMC: 3131958. DOI: 10.1038/cdd.2010.187. View

Liu Z, Naranjo A, Thiele C . CASZ1b, the short isoform of CASZ1 gene, coexpresses with CASZ1a during neurogenesis and suppresses neuroblastoma cell growth. PLoS One. 2011; 6(4):e18557. PMC: 3072398. DOI: 10.1371/journal.pone.0018557. View

10.

Braun D, Hou Y, Bakouny Z, Ficial M, Sant Angelo M, Forman J . Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020; 26(6):909-918. PMC: 7499153. DOI: 10.1038/s41591-020-0839-y. View

11.

Motzer R, Robbins P, Powles T, Albiges L, Haanen J, Larkin J . Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020; 26(11):1733-1741. PMC: 8493486. DOI: 10.1038/s41591-020-1044-8. View

12.

Mcdermott D, Huseni M, Atkins M, Motzer R, Rini B, Escudier B . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018; 24(6):749-757. PMC: 6721896. DOI: 10.1038/s41591-018-0053-3. View

13.

Braun D, Ishii Y, Walsh A, Van Allen E, Wu C, Shukla S . Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncol. 2019; 5(11):1631-1633. PMC: 6735411. DOI: 10.1001/jamaoncol.2019.3158. View

14.

Ascierto M, McMiller T, Berger A, Danilova L, Anders R, Netto G . The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunol Res. 2016; 4(9):726-33. PMC: 5584610. DOI: 10.1158/2326-6066.CIR-16-0072. View

15.

Chen Z, Luo Z, Zhang D, Li H, Liu X, Zhu K . TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource. Genomics Proteomics Bioinformatics. 2022; 21(2):337-348. PMC: 10626175. DOI: 10.1016/j.gpb.2022.08.004. View

16.

Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J . MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2017; 10(3):277-288. DOI: 10.2217/epi-2017-0118. View

17.

Robertson K . DNA methylation and human disease. Nat Rev Genet. 2005; 6(8):597-610. DOI: 10.1038/nrg1655. View

18.

Jian H, Poetsch A . : Current Implications in Cardiovascular Diseases and Cancers. Biomedicines. 2023; 11(7). PMC: 10377389. DOI: 10.3390/biomedicines11072079. View

19.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

20.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View